Skip to main content
Longitudinal follow up of serological response in children treated for Chagas disease
PLoS Neglected Tropical Diseases
  • Guillermo Moscatelli, Hospital de Ninos Ricardo Gutierrez
  • Samanta Moroni, Hospital de Ninos Ricardo Gutierrez
  • Facundo García Bournissen, Hospital de Ninos Ricardo Gutierrez
  • Nicolás González, Hospital de Ninos Ricardo Gutierrez
  • Griselda Ballering, Hospital de Ninos Ricardo Gutierrez
  • Alejandro Schijman, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Buenos Aires
  • Ricardo Corral, Hospital de Ninos Ricardo Gutierrez
  • Margarita Bisio, Hospital de Ninos Ricardo Gutierrez
  • Héctor Freilij, Hospital de Ninos Ricardo Gutierrez
  • Jaime Altcheh, Hospital de Ninos Ricardo Gutierrez
Document Type
Publication Date
URL with Digital Object Identifier

Background Evaluation of therapeutic response in chronic Chagas disease is a major challenge, due to prolonged persistence of Trypanosoma cruzi-specific antibodies, lack of sensitivity of parasitological tests, and need for long-term follow-up to observe negative seroconversion of conventional serological tests (CS). The objective of this study was to evaluate F2/3-ELISA serology, a promising early biomarker of therapeutic response, and T.cruzi Polymerase chain reaction (PCR) for T. cruzi Deoxyribonucleic acid (DNA), for neonatal diagnosis and evaluation of parasitemia after treatment. Methods Prospective cohort study, with three-year clinical, serological and parasitological follow-up of pediatric Chagas disease patients treated with benznidazole. Serology was evaluated by Enzyme-Linked ImmunoSorbent Assay (ELISA), Indirect hemagglutination (IHA) and F2/3- ELISA; Parasitemia by microhematocrit (MH) and PCR. Results A cohort of 107 pediatric patients treated with benznidazole was enrolled in the study. ELISA and IHA were initially reactive in 100% of patients, F2/3-ELISA serology was reactive in 80% (86/107) and 91% (97/107) had detectable parasitemia. Seventy-six (71%) patients completed at least 36 months of serological follow up after treatment. Although a similar decreasing linear trend was observed for all serological tests, F2/3-ELISA presented earlier, age dependent, negative seroconversion compared to CS. All patients reaching undetectable CS titers had previously seroreverted by F2/3-ELISA. All patients with persistently decreasing antibody titers had negative PCRs throughout the follow up period. No new cardiological lesions were observed during the 3 years follow-up period. Conclusions The data reported here, using CS, F2/3 ELISA and PCR provide support for the efficacy of benznidazole in congenital Chagas diseases. These results provide support for scaling up of screening, diagnosis and access to benznidazole treatment.

Citation Information
Guillermo Moscatelli, Samanta Moroni, Facundo García Bournissen, Nicolás González, et al.. "Longitudinal follow up of serological response in children treated for Chagas disease" PLoS Neglected Tropical Diseases Vol. 13 Iss. 8 (2019)
Available at: